<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Hoogeveen, A.T.</title>
    <link>http://repub.eur.nl/res/aut/2408/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Loss of MTG16a (CBFA2T3), a novel rDNA repressor, leads to increased ribogenesis and disruption of breast acinar morphogenesis (Article)</title>
      <link>http://repub.eur.nl/res/pub/28599/</link>
      <pubDate>2010-06-01T00:00:00Z</pubDate>
      <description>Human MTG16a (CBFA2T3), a chromatin repressor with nucleolar localization, was described to act as a suppressor of breast tumourigenesis. Here we show that MTG16a is a novel ribosomal gene repressor, which can counteract MYC-driven activation of ribosomal RNA (rRNA) transcription. We also show that either knocking down MTG16a by RNA interference, or sequestering MTG16a outside the nucleolus of human breast epithelial cells, hampers acinar morphogenesis concomitant with up-regulation of rRNA synthesis and increased ribogenesis. This is the first demonstration that loss of MTG16a function in the nucleolus of breast epithelial cells can induce morphological and molecular changes typical of breast cancer initiation. © 2009 The Authors Journal compilation </description>
    </item> <item>
      <title>Novel RNA-binding properties of the MTG chromatin regulatory proteins (Article)</title>
      <link>http://repub.eur.nl/res/pub/30329/</link>
      <pubDate>2008-10-24T00:00:00Z</pubDate>
      <description>Background: The myeloid translocation gene (MTG) proteins are non-DNA-binding transcriptional regulators capable of interacting with chromatin modifying proteins. As a consequence of leukemia-associated chromosomal translocations, two of the MTG proteins, MTG8 and MTG16, are fused to the DNA-binding domain of AML1, a transcriptional activator crucial for hematopoiesis. The AML1-MTG fusion proteins, as the wild type MTGs, display four conserved homology regions (NHR1-4) related to the Drosophila nervy protein. Structural protein analyses led us to test the hypothesis that specific MTG domains may mediate RNA binding. Results: By using an RNA-binding assay based on synthetic RNA homopolymers and a panel of MTG deletion mutants, here we show that all the MTG proteins can bind RNA. The RNA-binding properties can be traced to two regions: the Zinc finger domains in the NHR4, which mediate Zinc-dependent RNA binding, and a novel short basic region (SBR) upstream of the NHR2, which mediates Zinc-independent RNA binding. The two AML1-MTG fusion proteins, retaining both the Zinc fingers domains and the SBR, also display RNA-binding properties. Conclusion: Evidence has been accumulating that RNA plays a role in transcriptional control. Both wild type MTGs and chimeric AML1-MTG proteins display in vitro RNA-binding properties, thus opening new perspectives on the possible involvement of an RNA component in MTG-mediated chromatin regulation. </description>
    </item> <item>
      <title>A distinct epigenetic signature at targets of a leukemia protein (Article)</title>
      <link>http://repub.eur.nl/res/pub/36939/</link>
      <pubDate>2007-02-19T00:00:00Z</pubDate>
      <description>Background: Human myelogenous leukemia characterized by either the non random t(8; 21)(q22; q22) or t(16; 21)(q24; q22) chromosome translocations differ for both their biological and clinical features. Some of these features could be consequent to differential epigenetic transcriptional deregulation at AML1 targets imposed by AML1-MTG8 and AML1-MTG16, the fusion proteins deriving from the two translocations. Preliminary findings showing that these fusion proteins lead to transcriptional downregulation of AML1 targets, marked by repressive chromatin changes, would support this hypothesis. Here we show that combining conventional global gene expression arrays with the power of bioinformatic genomic survey of AML1-consensus sequences is an effective strategy to identify AML1 targets whose transcription is epigenetically downregulated by the leukemia-associated AML1-MTG16 protein. Results: We interrogated mouse gene expression microarrays with probes generated either from 32D cells infected with a retroviral vector carrying AML1-MTG16 and unable of granulocyte differentiation and proliferation in response to the granulocyte colony stimulating factor (G-CSF), or from 32D cells infected with the cognate empty vector. From the analysis of differential gene expression alone (using as criteria a p value &lt; 0.01 and an absolute fold change &gt; 3), we were unable to conclude which of the 37 genes downregulated by AML1-MTG16 were, or not, direct AML1 targets. However, when we applied a bioinformatic approach to search for AML1-consensus sequences in the 10 Kb around the gene transcription start sites, we closed on 17 potential direct AML1 targets. By focusing on the most significantly downregulated genes, we found that both the AML1-consensus and the transcription start site chromatin regions were significantly marked by aberrant repressive histone tail changes. Further, the promoter of one of these genes, containing a CpG island, was aberrantly methylated. Conclusion: This study shows that a leukemia-associated fusion protein can impose a distinct epigenetic repressive signature at specific sites in the genome. These findings strengthen the conclusion that leukemia-specific oncoproteins can induce non-random epigenetic changes. </description>
    </item> <item>
      <title>Loss of FMR1 hypermethylation in somatic cell heterokaryons. (Article)</title>
      <link>http://repub.eur.nl/res/pub/13502/</link>
      <pubDate>2004-12-01T00:00:00Z</pubDate>
      <description>Fragile X syndrome is associated with a trinucleotide (CGG) repeat
      expansion in the 5'-untranslated region of the FMR1 gene and
      hypermethylation of the FMR1 promoter. Rare cases of clinically normal
      males (HFM) have been identified with an expanded CGG repeat; however,
      here, the FMR1 promoter is not methylated. Using classical complementation
      (cell fusion) studies, we analyzed if possible differences in the genetic
      background between HFM and cells from individuals with fragile X syndrome
      (FX cells) could have an influence on the methylation status of the FMR1
      promoter. We observed that demethylation of the hypermethylated FMR1
      promoter can occur when FX cells are complemented (by cell fusion) with
      cells from HFM as well as with cells from control individuals. The
      observed demethylation is specific and can happen without DNA replication.
      In contrast, demethylation was not observed when cells from unrelated
      individuals with fragile X syndrome were fused, indicating that FX cells
      have lost the necessary factor(s) to demethylate the aberrantly methylated
      FMR1 promoter.</description>
    </item> <item>
      <title>Fxr1 knockout mice show a striated muscle phenotype: implications for Fxr1p function in vivo. (Article)</title>
      <link>http://repub.eur.nl/res/pub/13369/</link>
      <pubDate>2004-07-01T00:00:00Z</pubDate>
      <description>FXR1 is one of the two known homologues of FMR1. FXR1 shares a high degree
      of sequence homology with FMR1 and also encodes two KH domains and an RGG
      domain, conferring RNA-binding capabilities. In comparison with FMRP, very
      little is known about the function of FXR1P in vivo. Mouse knockout (KO)
      models exist for both Fmr1 and Fxr2. To study the function of Fxr1 in
      vivo, we generated an Fxr1 KO mouse model. Homozygous Fxr1 KO neonates die
      shortly after birth most likely due to cardiac or respiratory failure.
      Histochemical analyses carried out on both skeletal and cardiac muscles
      show a disruption of cellular architecture and structure in E19 Fxr1
      neonates compared with wild-type (WT) littermates. In WT E19 skeletal and
      cardiac muscles, Fxr1p is localized to the costameric regions within the
      muscles. In E19 Fxr1 KO littermates, in addition to the absence of Fxr1p,
      costameric proteins vinculin, dystrophin and alpha-actinin were found to
      be delocalized. A second mouse model (Fxr1 + neo), which expresses
      strongly reduced levels of Fxr1p relative to WT littermates, does not
      display the neonatal lethal phenotype seen in the Fxr1 KOs but does
      display a strongly reduced limb musculature and has a reduced life span of
      approximately 18 weeks. The results presented here point towards a role
      for Fxr1p in muscle mRNA transport/translation control similar to that
      seen for Fmrp in neuronal cells.</description>
    </item> <item>
      <title>The FMR1 CGG repeat mouse displays ubiquitin-positive intranuclear neuronal inclusions; implications for the cerebellar tremor/ataxia syndrome (Article)</title>
      <link>http://repub.eur.nl/res/pub/10126/</link>
      <pubDate>2003-01-01T00:00:00Z</pubDate>
      <description>Recent studies have reported that alleles in the premutation range in the
      FMR1 gene in males result in increased FMR1 mRNA levels and at the same
      time mildly reduced FMR1 protein levels. Some elderly males with
      premutations exhibit an unique neurodegenerative syndrome characterized by
      progressive intention tremor and ataxia. We describe neurohistological,
      biochemical and molecular studies of the brains of mice with an expanded
      CGG repeat and report elevated Fmr1 mRNA levels and intranuclear
      inclusions with ubiquitin, Hsp40 and the 20S catalytic core complex of the
      proteasome as constituents. An increase was observed of both the number
      and the size of the inclusions during the course of life, which correlates
      with the progressive character of the cerebellar tremor/ataxia syndrome in
      humans. The observations in expanded-repeat mice support a direct role of
      the Fmr1 gene, by either CGG expansion per se or by mRNA level, in the
      formation of the inclusions and suggest a correlation between the presence
      of intranuclear inclusions in distinct regions of the brain and the
      clinical features in symptomatic premutation carriers. This mouse model
      will facilitate the possibilities to perform studies at the molecular
      level from onset of symptoms until the final stage of the disease.</description>
    </item> <item>
      <title>Knockout mouse model for Fxr2: a model for mental retardation (Article)</title>
      <link>http://repub.eur.nl/res/pub/9866/</link>
      <pubDate>2002-01-01T00:00:00Z</pubDate>
      <description>Fragile X syndrome is a common form of mental retardation caused by the
      absence of the FMR1 protein, FMRP. Fmr1 knockout mice exhibit a phenotype
      with some similarities to humans, such as macro-orchidism and behavioral
      abnormalities. Two homologs of FMRP have been identified, FXR1P and FXR2P.
      These proteins show high sequence similarity, including all functional
      domains identified in FMRP, such as RNA binding domains. They have an
      overlap in tissue distribution to that of FMRP. Interactions between the
      three FXR proteins have also been described. FXR2P shows high expression
      in brain and testis, like FMRP. To study the function of FXR2P, we
      generated an Fxr2 knockout mouse model. No pathological differences
      between knockout and wild-type mice were found in brain or testis. Given
      the behavioral phenotype in fragile X patients and the phenotype
      previously reported for the Fmr1 knockout mouse, we performed a thorough
      evaluation of the Fxr2 knockout phenotype using a behavioral test battery.
      Fxr2 knockout mice were hyperactive (i.e. traveled a greater distance,
      spent more time moving and moved faster) in the open-field test, impaired
      on the rotarod test, had reduced levels of prepulse inhibition, displayed
      less contextual conditioned fear, impaired at locating the hidden platform
      in the Morris water task and were less sensitive to a heat stimulus.
      Interestingly, there are some behavioral phenotypes in Fxr2 knockout mice
      which are similar to those observed in Fmr1 knockout mice, but there are
      also some different behavioral abnormalities that are only observed in the
      Fxr2 mutant mice. The findings implicate a role for Fxr2 in central
      nervous system function.</description>
    </item> <item>
      <title>The fragile X-related proteins FXR1P and FXR2P contain a functional nucleolar-targeting signal equivalent to the HIV-1 regulatory proteins (Article)</title>
      <link>http://repub.eur.nl/res/pub/9408/</link>
      <pubDate>2000-01-01T00:00:00Z</pubDate>
      <description>Fragile X syndrome is caused by the absence of the fragile X
          mental-retardation protein (FMRP). FMRP and the fragile X-related proteins
          1 and 2 (FXR1P and FXR2P) form a gene family with functional similarities,
          such as RNA binding, polyribosomal association and nucleocytoplasmic
          shuttling. In a previous study, we found that FMRP and FXR1P shuttle
          between cytoplasm and nucleoplasm, while FXR2P shuttles between cytoplasm
          and nucleolus. The nuclear and nucleolar-targeting properties of these
          proteins were investigated further. Here, we show that FXR2P contains in
          its C-terminal part, a stretch of basic amino acids 'RPQRRNRSRRRRFR' that
          resemble the nucleolar-targeting signal (NoS) of the viral protein Rev.
          This particular sequence is also present within exon 15 of the FXR1 gene.
          This exon undergoes alternative splicing and is therefore only present in
          some of the FXR1P isoforms. We investigated the intracellular distribution
          of various FXR1P isoforms with (iso-e and iso-f) and without (iso-d) the
          potential NoS in transfected COS cells treated with the nuclear export
          inhibitor leptomycin-B. Both iso-e and iso-f showed a nucleolar
          localization, as observed for FXR2P; iso-d was detected in the
          nucleo-plasm outside the nucleoli. Further, when a labelled 16-residue
          synthetic peptide corresponding to the NoS of FXR1P was added to human
          fibroblast cultures a clear nucleolar signal was observed. Based on these
          data we argue that the intranuclear distribution of FXR2P and FXR1P
          isoforms is very likely to be mediated by a similar NoS localized in their
          C-terminal region. This domain is absent in some FXR1P isoforms as well as
          in all FMRP isoforms, suggesting functional differences for this family of
          proteins, possibly related to RNA metabolism in different tissues.</description>
    </item> <item>
      <title>Mutation-dependent aggregation of tau protein and its selective depletion from the soluble fraction in brain of P301L FTDP-17 patients (Article)</title>
      <link>http://repub.eur.nl/res/pub/9554/</link>
      <pubDate>2000-01-01T00:00:00Z</pubDate>
      <description>Mutations in the gene for the microtubule-associated protein tau are
          associated with frontotemporal dementia and parkinsonism linked to
          chromosome 17 (FTDP-17). In this study we compared the presence of the
          P301L mutated tau protein from brain material of patients with that of the
          normal 4-repeat, using polyclonal antibodies specific for the P301L point
          mutation and its normal counterpart. We determined the relative ratio of
          mutated versus normal tau protein in the sarkosyl-soluble and -insoluble
          protein fractions from several brain regions. Although mutated and normal
          tau proteins are both present in the sarkosyl-insoluble deposits,
          quantitative analysis showed that the mutated protein is the major
          component. In the sarkosyl-soluble fraction of frontal and temporal cortex
          the overall ratio of 3-repeat versus 4-repeat tau isoforms is unchanged
          but there is a dramatic depletion of mutant tau protein. Furthermore, we
          observed an increase in tau-immunoreactive cleavage products with the
          P301L antibody, suggesting that the mutant protein is partly resistant to
          degradation and this is confirmed by pulse-chase experiments. This is the
          first direct evidence using patient material that shows a selective
          aggregation of mutant tau protein resulting in sarkosyl-insoluble deposits
          and the specific depletion of mutated tau protein in the soluble fraction.</description>
    </item> <item>
      <title>Different targets for the fragile X-related proteins revealed by their distinct nuclear localizations (Article)</title>
      <link>http://repub.eur.nl/res/pub/9073/</link>
      <pubDate>1999-01-01T00:00:00Z</pubDate>
      <description>Fragile X syndrome is caused by the absence of the fragile X mental
          retardation protein (FMRP). FMRP and its structural homologues FXR1P and
          FXR2P form a family of RNA-binding proteins (FXR proteins). The three
          proteins associate with polyribosomes as cytoplasmic mRNP particles. Here
          we show that small amounts of FMRP, FXR1P and FXR2P shuttle between
          cytoplasm and nucleus. Mutant FMRP of a severely affected fragile X
          patient (FMRPI304N) does not associate with polyribosomes and shuttles
          more frequently than normal FMRP, indicating that the association with
          polyribosomes regulates the shuttling process. Using leptomycin B we
          demonstrate that transport of the FXR proteins out of the nucleus is
          mediated by the export receptor exportin1. Finally, inactivation of the
          nuclear export signal in two FXR proteins shows that FMRP shuttles between
          cytoplasm and nucleoplasm, while FXR2P shuttles between cytoplasm and
          nucleolus. Therefore, molecular dissection of the shuttling routes used by
          the FXR proteins suggests that they transport different RNAs.</description>
    </item> <item>
      <title>Oligomerization properties of fragile-X mental-retardation protein (FMRP) and the fragile-X-related proteins FXR1P and FXR2P (Article)</title>
      <link>http://repub.eur.nl/res/pub/9181/</link>
      <pubDate>1999-01-01T00:00:00Z</pubDate>
      <description>The absence of fragile-X mental-retardation protein (FMRP) results in
          fragile-X syndrome. Two other fragile-X-related (FXR) proteins have been
          described, FXR1P and FXR2P, which are both very similar in amino acid
          sequence to FMRP. Interaction between the three proteins as well as with
          themselves has been demonstrated. The FXR proteins are believed to play a
          role in RNA metabolism. To characterize a possible functional role of the
          interacting proteins the complex formation of the FXR proteins was studied
          in mammalian cells. Double immunofluorescence analysis in COS cells
          over-expressing either FMRP ISO12/FXR1P or FMRP ISO12/FXR2P confirmed
          heterotypic interactions. However, Western-blotting studies on cellular
          homogenates containing physiological amounts of the three proteins gave
          different indications. Gel-filtration experiments under physiological as
          well as EDTA conditions showed that the FXR proteins were in complexes of
          &gt;600 kDa, as parts of messenger ribonuclear protein (mRNP) particles
          associated with polyribosomes. Salt treatment shifted FMRP, FXR1P and
          FXR2P into distinct intermediate complexes, with molecular masses between
          200 and 300 kDa. Immunoprecipitations of FMRP as well as FXR1P from the
          dissociated complexes revealed that the vast majority of the FXR proteins
          do not form heteromeric complexes. Further analysis by [(35)S]methionine
          labelling in vivo followed by immunoprecipitation indicated that no
          proteins other than the FXR proteins were present in these complexes.
          These results suggest that the FXR proteins form homo-multimers
          preferentially under physiological conditions in mammalian cells, and
          might participate in mRNP particles with separate functions.</description>
    </item> <item>
      <title>Differential expression of FMR1, FXR1 and FXR2 proteins in human brain and testis (Article)</title>
      <link>http://repub.eur.nl/res/pub/8709/</link>
      <pubDate>1997-01-01T00:00:00Z</pubDate>
      <description>Lack of expression of the fragile X mental retardation protein (FMRP)
      results in mental retardation and macroorchidism, seen as the major
      pathological symptoms in fragile X patients. FMRP is a cytoplasmic
      RNA-binding protein which cosediments with the 60S ribosomal subunit.
      Recently, two proteins homologous to FMRP were discovered: FXR1 and FXR2.
      These novel proteins interact with FMRP and with each other and they are
      also associated with the 60S ribosomal subunit. Here, we studied the
      expression pattern of the three proteins in brain and testis by
      immunohistochemistry. In adult brain, FMR1, FXR1 and FXR2 proteins are
      coexpressed in the cytoplasm of specific differentiated neurons only.
      However, we observed a different expression pattern in fetal brain as well
      as in adult and fetal testis, suggesting independent functions for the
      three proteins in those tissues during embryonic development and adult
      life.</description>
    </item> <item>
      <title>FMRP is associated to the ribosomes via RNA (Article)</title>
      <link>http://repub.eur.nl/res/pub/8620/</link>
      <pubDate>1996-01-01T00:00:00Z</pubDate>
      <description>The FMR1 transcript is alternatively spliced and generates different
      splice variants coding for FMR1 proteins (FMRP) with a predicted molecular
      mass of 70-80 kDa. FMRP is widely expressed and localized in the
      cytoplasm. To study a possible interaction with other cellular components,
      FMRP was isolated and characterized under non-denaturing conditions. Under
      physiological salt conditions FMRP appears to have a molecular mass of &gt;
      600 kDa, indicating a binding to other cellular components. This
      interaction is disrupted in the presence of high salt concentrations. The
      dissociation conditions to free FMRP from the complex are similar to the
      dissociation of FMRP from RNA as shown before. The binding of FMRP from
      the complex is also disrupted by RNAse treatment. That the association of
      FMRP to a high molecular weight complex possibly occurs via RNA, is
      further supported by the observation that the binding of FMRP, containing
      an lle304Asn substitution, to the high molecular weight complex is
      reduced. An equal reduced binding of mutated FMRP to RNA in vitro was
      observed before under the same conditions. The reduced binding of FMRP
      with the lle304Asn substitution further indicates that the interaction to
      the complex indeed occurs via FMRP and not via other RNA binding proteins.
      In a reconstitution experiment where the low molecular mass FMRP (70-80
      kDa) is mixed with a reticulocyte lysate (enriched in ribosomes) it was
      shown that FMRP can associate to ribosomes and that this binding most
      likely occurs via RNA.</description>
    </item>
  </channel>
</rss>